Medical Aspects of Chemical Warfare (2008) - The Black Vault
Medical Aspects of Chemical Warfare (2008) - The Black Vault Medical Aspects of Chemical Warfare (2008) - The Black Vault
Riot Control AgentsNC); or Cool It! wipes and spray (Defense Technology,Casper, Wyo); claim to help decontaminate andreduce pain in people exposed to pepper sprays andother RCAs. 191–193TreatmentSkinSkin erythema that appears early (up to 1 hourafter exposure) is transient and usually does notrequire treatment. Delayed-onset erythema (irritantdermatitis) can be treated with a bland lotion suchas calamine lotion or topical corticosteroid preparations(eg, 0.10% triamcinolone acetonide, 0.025%fluocinolone acetonide, 0.05% flurandrenolone, orbetamethasone-17-valerate). Cosmetics, includingfoundation and false eyelashes, can trap agent andshould be removed to insure complete decontamination.22 When the patient has been exposed to OC, theuse of creams or ointments should be delayed for 6hours after exposure. 194 Patients with blisters shouldbe managed as having a second-degree burn. 195 Acutecontact dermatitis that is oozing should be treatedwith wet dressings (moistened with fluids such as 1:40Burow solution or colloidal solution) for 30 minutes,three times daily. 3,187 Topical steroids should be appliedimmediately following the wet dressing. Appropriateantibiotics should be given for secondary infection, andoral antihistamines for itching. 3,187 Vesicating lesionshave been successfully treated with compresses of acold silver nitrate solution (1:1,000) for 1 hour, appliedsix times daily. 75 One person with severe lesions andmarked discomfort was given a short course of an oralsteroid. An antibiotic ointment was applied locally,but systemic antibiotics were not used. 75 With severeblistering resulting in second-degree burns, skin pigmentationchanges can occur. 4EyeThe effects of RCAs on the eyes are self-limiting anddo not normally require treatment; however, if largeparticles of solid agent are in the eye, the patient shouldbe treated as if for exposure to corrosive materials. 195The individual should be kept from rubbing the eyes,which can rub particles or agent into the eye and causedamage. 24 Contact lenses should be removed. 194Yih recommends that before irrigating eyes contaminatedwith CS, they should be blown dry, directly,with an electric fan, which helps dissolved particlesevaporate and rapidly reduces pain (irrigating theeyes before drying causes additional, unnecessary,pain. 82 However, other researchers note that if Yih’srecommendations are used, the care provider mustbe certain that the agent is CS, for such a delay indecontaminating more toxic agents such as ammoniawould result in severe eye injury. With all agents, theaffected eyes should be thoroughly flushed with copiousamounts of normal saline or water for severalminutes (some sources suggest 10 minutes) to removethe agent. 194Eye injury assessment should include a slit lampexamination with fluorescein staining to evaluate forcorneal abrasions that could be caused by rubbingparticles of the agent into the eye. 4,196 Patients shouldbe closely observed for development of corneal opacityand iritis, particularly those who have been exposedto CN or CA. A local anesthetic can be used for severepain, but continued anesthetic use should be restricted.If the lesion is severe, the patient should be sent fordefinitive ophthalmologic treatment.Viala et al 197 reported a study of five French gendarmeswho had CS exposure and were decontaminatedwith Diphoterine (Prevor, Valmondois, France),which dramatically resolved the effects in four ofthem. The researchers also recommended using it asa prophylaxis to reduce or prevent lacrimation, eyeirritation, and blepharospasm. 197Respiratory TractTypically, RCA-induced cough, chest discomfort,and mild dyspnea are resolved within 30 minutes afterexposure to clean air. However, both the animal data(detailed in the section on CS) and clinical experiencewith an infant exposed to CS 198 suggest that severerespiratory effects may not become manifest until 12to 24 hours after exposure. If persistent bronchospasmlasting several hours develops, systemic or inhaledbronchodilators (eg, albuterol 0.5%) can be effectivein reducing the condition. 4,196Individuals with prolonged dyspnea or objectivesigns such as coughing, sneezing, breath holding, andexcessive salivation should be hospitalized under carefulobservation. Treatment in these cases may includethe introduction of systemic aminophylline and systemicglucocorticosteroids. 4,55 A chest radiograph canassist in diagnosis and treatment for patients with significantrespiratory complaints. 196 If respiratory failureoccurs, the use of extracorporeal membrane oxygenationcan be effective without causing long-term damageto the lungs. 4,199 High-pressure ventilation, whichcan cause lung scarring, should not be used. Althoughpeople with chronic bronchitis have been exposed toRCAs without effects, any underlying lung disease(eg, asthma, which affects one person in six) might beexacerbated by exposure to CS. 3,200 In most cases the471
Medical Aspects of Chemical Warfarerespiratory system quickly recovers from acute exposureto RCAs, but prolonged exposure can predisposethe casualty to secondary infections. Further careshould be as described in Chapter 10, Toxic InhalationalInjury and Toxic Industrial Chemicals.Cardiovascular SystemTransient hypertension and tachycardia have beennoted after exposure to RCAs, primarily because of theanxiety or pain of exposure rather than a pharmacologicaleffect of the compound. 201 Whatever the cause,adverse effects may be seen in individuals with hypertension,cardiovascular disease, or an aneurysm.Laboratory FindingsNo specific laboratory study abnormalities are helpfulin diagnosing RCA exposure. Appropriate tests canbe ordered to guide treatment if respiratory tract or skininfection is suspected. Arterial blood gasses can be orderedif there is a concern about adequate ventilation. 196New Developments and Future UseAs documented throughout this chapter, the military’sinterest in and occasional use of RCAs has notonly kept pace with their development, but in manycases the military has spearheaded the effort. Althoughmost of this historical activity predated the currentregulations guiding research, development, and useof RCAs (ie, prior to the Chemical Weapons Convention),it is probable that this trend will continue intothe future.Recent years have witnessed a fundamental methodologicalshift in biomedical science research. Thetraditional method of identifying biologically activecompounds before determining their application todisease has been replaced, in part, by identifyingbiological targets (ie, protein receptors) first, followedby identifying the chemical compounds capable ofbinding to the targets and altering their function. Theadvancement of microarray, proteomics, toxicogenomics,database mining techniques, and computationalmodeling techniques has greatly accelerated the abilityto identify novel biological targets with desiredphysiological effects. Likewise, high-throughputtechnologies capable of identifying biologically activecompounds such as in-vitro tissue culture systemsintegrated with automated robotics test stations,combinatorial chemistry, and quantitative structureactivity relationship methods have accelerated newdrug discovery. New RCAs are likely to be a productof this research.Neuropharmacology is an area of biomedicalresearch likely to yield future RCAs. The increasedincidence and awareness of neurological disorders inthe general population, such as Alzheimer disease inthe elderly and attention deficit disorders in children,ensure a healthy research base aimed at discoveringbioactive compounds capable of altering cognitivefunctions, perception, mood, emotions, bodily control,and alertness.Although OC and CS, today’s RCAs of choice, arevery safe if deployed appropriately, more research isneeded to illuminate the full health consequences oftheir use. The limited financial resources of the military’schemical defense programs dictate that fundsbe spent on measures to defend against more lethalchemical agents and toxins that could be used byAmerica’s enemies. Law enforcement agencies andmanufacturers also have limited resources to thoroughlyinvestigate the safety of these compounds.Currently, federal resources are more wisely used toprevent disease and address healthcare issues that affectthe population at large.The control of the administration of RCAs might bedifficult to regulate, particularly in the areas and underthe circumstances in which the use of RCAs has apparentlybeen misused (eg, the West Bank and Gaza Strip,and Seoul, South Korea). Despite the concern aboutthe occasional loss of life of those exposed to RCAsor the occasional injury among innocent bystanders,there is serious doubt that a prohibition of the use ofRCAs would be effective. Although in some instancesdialogue and negotiation should precede the use ofRCAs, these agents have proved effective in curbingdamage to property and persons in threatening situations.Although RCAs sometimes cause permanentinjury or death, especially when used in enclosedspaces or against those with existing cardiopulmonarycompromise, in most situations the amount of injuryis small compared to what might have happened ifmore extreme measures (physical or lethal force) hadbeen used.SUMMARYRCAs are intended to harass or to cause temporaryincapacitation. The intended target might be rioters ina civil disturbance, or if approved by the president ofthe United States, the military in an armed conflict.Although developed to have a high margin of safety,RCAs can cause injury or death when used in spaces472
- Page 443 and 444: Medical Aspects of Chemical Warfare
- Page 445 and 446: Medical Aspects of Chemical Warfare
- Page 447 and 448: Medical Aspects of Chemical Warfare
- Page 449 and 450: Medical Aspects of Chemical Warfare
- Page 451 and 452: Medical Aspects of Chemical Warfare
- Page 453 and 454: Medical Aspects of Chemical Warfare
- Page 455 and 456: Medical Aspects of Chemical Warfare
- Page 457 and 458: Medical Aspects of Chemical Warfare
- Page 459 and 460: Medical Aspects of Chemical Warfare
- Page 461 and 462: Medical Aspects of Chemical Warfare
- Page 463 and 464: Medical Aspects of Chemical Warfare
- Page 465 and 466: Medical Aspects of Chemical Warfare
- Page 467 and 468: Medical Aspects of Chemical Warfare
- Page 469 and 470: Medical Aspects of Chemical Warfare
- Page 471 and 472: Medical Aspects of Chemical Warfare
- Page 473 and 474: Medical Aspects of Chemical Warfare
- Page 475 and 476: Medical Aspects of Chemical Warfare
- Page 477 and 478: Medical Aspects of Chemical Warfare
- Page 479 and 480: Medical Aspects of Chemical Warfare
- Page 481 and 482: Medical Aspects of Chemical Warfare
- Page 483 and 484: Medical Aspects of Chemical Warfare
- Page 485 and 486: Medical Aspects of Chemical Warfare
- Page 487 and 488: Medical Aspects of Chemical Warfare
- Page 489 and 490: Medical Aspects of Chemical Warfare
- Page 491 and 492: Medical Aspects of Chemical Warfare
- Page 493: Medical Aspects of Chemical Warfare
- Page 497 and 498: Medical Aspects of Chemical Warfare
- Page 499 and 500: Medical Aspects of Chemical Warfare
- Page 501 and 502: Medical Aspects of Chemical Warfare
- Page 503 and 504: Medical Aspects of Chemical Warfare
- Page 505 and 506: Medical Aspects of Chemical Warfare
- Page 507 and 508: Medical Aspects of Chemical Warfare
- Page 509 and 510: Medical Aspects of Chemical Warfare
- Page 511 and 512: Medical Aspects of Chemical Warfare
- Page 513 and 514: Medical Aspects of Chemical Warfare
- Page 515 and 516: Medical Aspects of Chemical Warfare
- Page 517 and 518: Medical Aspects of Chemical Warfare
- Page 519 and 520: Medical Aspects of Chemical Warfare
- Page 521 and 522: Medical Aspects of Chemical Warfare
- Page 523 and 524: Medical Aspects of Chemical Warfare
- Page 525 and 526: Medical Aspects of Chemical Warfare
- Page 527 and 528: Medical Aspects of Chemical Warfare
- Page 529 and 530: Medical Aspects of Chemical Warfare
- Page 531 and 532: Medical Aspects of Chemical Warfare
- Page 534 and 535: Triage of Chemical CasualtiesChapte
- Page 536 and 537: Triage of Chemical Casualtiesreceiv
- Page 538 and 539: Triage of Chemical Casualtiesentran
- Page 540 and 541: Triage of Chemical Casualtiescatego
- Page 542 and 543: Triage of Chemical CasualtiesIn a f
<strong>Medical</strong> <strong>Aspects</strong> <strong>of</strong> <strong>Chemical</strong> <strong>Warfare</strong>respiratory system quickly recovers from acute exposureto RCAs, but prolonged exposure can predisposethe casualty to secondary infections. Further careshould be as described in Chapter 10, Toxic InhalationalInjury and Toxic Industrial <strong>Chemical</strong>s.Cardiovascular SystemTransient hypertension and tachycardia have beennoted after exposure to RCAs, primarily because <strong>of</strong> theanxiety or pain <strong>of</strong> exposure rather than a pharmacologicaleffect <strong>of</strong> the compound. 201 Whatever the cause,adverse effects may be seen in individuals with hypertension,cardiovascular disease, or an aneurysm.Laboratory FindingsNo specific laboratory study abnormalities are helpfulin diagnosing RCA exposure. Appropriate tests canbe ordered to guide treatment if respiratory tract or skininfection is suspected. Arterial blood gasses can be orderedif there is a concern about adequate ventilation. 196New Developments and Future UseAs documented throughout this chapter, the military’sinterest in and occasional use <strong>of</strong> RCAs has notonly kept pace with their development, but in manycases the military has spearheaded the effort. Althoughmost <strong>of</strong> this historical activity predated the currentregulations guiding research, development, and use<strong>of</strong> RCAs (ie, prior to the <strong>Chemical</strong> Weapons Convention),it is probable that this trend will continue intothe future.Recent years have witnessed a fundamental methodologicalshift in biomedical science research. <strong>The</strong>traditional method <strong>of</strong> identifying biologically activecompounds before determining their application todisease has been replaced, in part, by identifyingbiological targets (ie, protein receptors) first, followedby identifying the chemical compounds capable <strong>of</strong>binding to the targets and altering their function. <strong>The</strong>advancement <strong>of</strong> microarray, proteomics, toxicogenomics,database mining techniques, and computationalmodeling techniques has greatly accelerated the abilityto identify novel biological targets with desiredphysiological effects. Likewise, high-throughputtechnologies capable <strong>of</strong> identifying biologically activecompounds such as in-vitro tissue culture systemsintegrated with automated robotics test stations,combinatorial chemistry, and quantitative structureactivity relationship methods have accelerated newdrug discovery. New RCAs are likely to be a product<strong>of</strong> this research.Neuropharmacology is an area <strong>of</strong> biomedicalresearch likely to yield future RCAs. <strong>The</strong> increasedincidence and awareness <strong>of</strong> neurological disorders inthe general population, such as Alzheimer disease inthe elderly and attention deficit disorders in children,ensure a healthy research base aimed at discoveringbioactive compounds capable <strong>of</strong> altering cognitivefunctions, perception, mood, emotions, bodily control,and alertness.Although OC and CS, today’s RCAs <strong>of</strong> choice, arevery safe if deployed appropriately, more research isneeded to illuminate the full health consequences <strong>of</strong>their use. <strong>The</strong> limited financial resources <strong>of</strong> the military’schemical defense programs dictate that fundsbe spent on measures to defend against more lethalchemical agents and toxins that could be used byAmerica’s enemies. Law enforcement agencies andmanufacturers also have limited resources to thoroughlyinvestigate the safety <strong>of</strong> these compounds.Currently, federal resources are more wisely used toprevent disease and address healthcare issues that affectthe population at large.<strong>The</strong> control <strong>of</strong> the administration <strong>of</strong> RCAs might bedifficult to regulate, particularly in the areas and underthe circumstances in which the use <strong>of</strong> RCAs has apparentlybeen misused (eg, the West Bank and Gaza Strip,and Seoul, South Korea). Despite the concern aboutthe occasional loss <strong>of</strong> life <strong>of</strong> those exposed to RCAsor the occasional injury among innocent bystanders,there is serious doubt that a prohibition <strong>of</strong> the use <strong>of</strong>RCAs would be effective. Although in some instancesdialogue and negotiation should precede the use <strong>of</strong>RCAs, these agents have proved effective in curbingdamage to property and persons in threatening situations.Although RCAs sometimes cause permanentinjury or death, especially when used in enclosedspaces or against those with existing cardiopulmonarycompromise, in most situations the amount <strong>of</strong> injuryis small compared to what might have happened ifmore extreme measures (physical or lethal force) hadbeen used.SUMMARYRCAs are intended to harass or to cause temporaryincapacitation. <strong>The</strong> intended target might be rioters ina civil disturbance, or if approved by the president <strong>of</strong>the United States, the military in an armed conflict.Although developed to have a high margin <strong>of</strong> safety,RCAs can cause injury or death when used in spaces472